These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA. Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174 [TBL] [Abstract][Full Text] [Related]
104. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma. Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543 [TBL] [Abstract][Full Text] [Related]
105. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma. Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495 [TBL] [Abstract][Full Text] [Related]
106. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785 [TBL] [Abstract][Full Text] [Related]
107. Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1. Shirani M; Levin S; Shebl B; Requena D; Finkelstein TM; Johnson DS; Ng D; Lalazar G; Heissel S; Hojrup P; Molina H; de Jong YP; Rice CM; Singhi AD; Torbenson MS; Coffino P; Lyons B; Simon SM Cancer Res; 2024 Jun; ():. PubMed ID: 38888469 [TBL] [Abstract][Full Text] [Related]
109. A framework for fibrolamellar carcinoma research and clinical trials. Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728 [TBL] [Abstract][Full Text] [Related]
110. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. Abdelhamed W; El-Kassas M World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219 [TBL] [Abstract][Full Text] [Related]
111. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms. Lalazar G; Simon SM Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565 [TBL] [Abstract][Full Text] [Related]
112. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature. Alshareefy Y; Shen CY; Prekash RJ Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175 [TBL] [Abstract][Full Text] [Related]
113. Fibrolamellar carcinoma: An entity all its own. O'Neill AF; Church AJ; Perez-Atayde AR; Shaikh R; Marcus KJ; Vakili K Curr Probl Cancer; 2021 Aug; 45(4):100770. PubMed ID: 34272087 [TBL] [Abstract][Full Text] [Related]